AMAmit Mhamane

Amit Mhamane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amit Mhamane has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Figure 1 from Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia

    by Juliano Machado, Vignesh Karthikaisamy, Hermine Mohr, Doris Kaltenecker, Pia Benedikt, Pauline Morigny, Amit Mhamane, Julia Geppert, Amy Rose Fumo, Kerstin Haase, et al.

    Circulating ADAMTSL4 levels are elevated in cancer cachexia. A and B, Relative body weight (BW) change (% of initial BW; A) and plasma ADAMTSL4 protein levels measured by ELISA (B) in cachectic C26 tumor-bearing mice (n = 8), noncachectic MC38 tumor-bearing mice (n = 10), and PBS-injected controls (n = 13). C and D, Relative BW change (C) and plasma ADAMTSL4 levels (D) in cachectic ApcMin/+ mice (n = 6) vs. wild-type (WT) littermates (n = 6). E and F, Relative BW change (E) and plasma ADAMTSL4 levels (F) in cachectic LLC tumor-bearing mice (n = 16) and PBS-injected controls (n = 11). G, Spearman correlation between plasma ADAMTSL4 levels and relative BW change across all mouse models (n = 70 XY pairs; pooled from A–F). H and I, Relative BW change (H) and circulating ADAMTSL4 levels (I; ELISA, log10 scale) in noncachectic (non–cancer cachexia, n = 20) and cachectic (cancer cachexia, n = 27) patients with colorectal cancer. J and K, Spearman correlations in patients with colorectal cancer between circulating ADAMTSL4 levels and relative BW change (J; n = 47 XY pairs) or cachexia grade (K; n = 47 XY pairs). L, ROC analysis comparing circulating ADAMTSL4 with established cachexia-associated biomarkers in patients with colorectal cancer. M and N, Relative BW change (M) and circulating ADAMTSL4 protein levels (N) in noncachectic (n = 30) and cachectic (n = 14) patients with LUAD from the TRACERx cohort. ADAMTSL4 was quantified by Olink proximity extension assay and is reported as NPX (log2-scaled relative abundance units). O and P, Spearman correlations between ADAMTSL4 NPX values and relative BW change (O; n = 44 XY pairs) or cachexia grade (P; n = 44 XY pairs) in patients with LUAD. Q, Kaplan–Meier analysis of OS in patients with NSCLC from the TRACERx cohort stratified by high vs. low circulating ADAMTSL4 (median NPX as cutoff). R, Kaplan–Meier analysis of disease-free survival in patients with NSCLC from the TRACERx cohort stratified by high vs. low circulating ADAMTSL4 (median NPX as cutoff). Data are presented as the mean ± SEM for mouse experiments (A–F). Relative BW change in patient cohorts (H and M) is shown with individual data points and mean ± SEM. For human biomarker group comparisons (I and N), data are shown as box-and-whisker plots with individual data points overlaid. Boxes indicate the interquartile range, center lines indicate the median, and whiskers indicate Tukey whiskers (1.5 × IQR). ELISA-based ADAMTSL4 concentrations in patients with colorectal cancer (I) are shown on a log10-transformed scale, whereas circulating ADAMTSL4 levels in patients with LUAD (N) are presented as NPX values (log2 scale). Due to differences in measurement platforms, values were analyzed within each cohort and were not directly compared across datasets. Statistical analysis: one-way ANOVA with Tukey multiple-comparisons test (A and B), two-tailed unpaired t test (C–F), and Spearman correlation (G). Human data were systematically evaluated for normality and outliers (ROUT, Q = 1%). For ELISA-based comparisons in colorectal cancer (I), distributions were right-skewed; therefore, two-tailed Mann–Whitney tests were used as the primary analysis, with Welch t test on log10-transformed data performed as sensitivity analysis (see “Methods”). Group comparisons in patients (H, I, M, and N) were analyzed using two-tailed Mann–Whitney tests. Correlation analyses in human cohorts (J, K, O, and P) were performed using two-tailed Spearman rank correlation. ROC analysis (L) was used to compare biomarker performance for discrimination of cachectic vs. noncachectic patients with colorectal cancer. Kaplan–Meier survival curves (Q and R) were compared using the log-rank (Mantel–Cox) test. Significance is denoted as *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; ns, not significant.

  • Open Access

    Figure 4 from Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia

    by Juliano Machado, Vignesh Karthikaisamy, Hermine Mohr, Doris Kaltenecker, Pia Benedikt, Pauline Morigny, Amit Mhamane, Julia Geppert, Amy Rose Fumo, Kerstin Haase, et al.

    Stable knockdown of tumor-derived ADAMTSL4 attenuates adipose tissue wasting, prolongs cachexia-related survival, and protects against cancer-induced cardiac atrophy. A–R, Mice were subcutaneously injected with PBS, control C26 cells (C26-shCtrl), or ADAMTSL4-depleted C26 cells (C26-shAdamtsl4). A, Schematic overview of the preclinical model used to assess the impact of tumor-derived ADAMTSL4 on adipose wasting, survival, and cardiac atrophy. B, Relative fat mass changes measured by EchoMRI. C, Mass of individual fat depots: iWAT, eWAT, and BAT. D, Plasma glycerol levels normalized to final fat mass. E, Selected GO terms from GSEA of eWAT comparing C26-shAdamtsl4 vs. C26-shCtrl tumor-bearing mice (see also Supplementary Data S7 and S8 for full GO term analysis results). F, mRNA expression of lipolysis-related genes and (G) fatty acid oxidation genes in eWAT, validating GSEA-enriched “fatty acid oxidation” and “lipid oxidation” terms. H, Western blot analysis of ATGL protein levels. I, Western blot analysis of autophagy-related proteins in eWAT, supporting the “autophagy” GO term from GSEA. J–R, Mice were subcutaneously inoculated with PBS (n = 5), C26-shCtrl cells (n = 6–7), or C26-shAdamtsl4 cells (n = 6–9). J, Tumor mRNA expression of Adamtsl4, Mki67, Bbc3, and Pmaip1 assessed by qPCR. K, Plasma ADAMTSL4 protein levels measured by Western blot. L, Kaplan–Meier curve showing percentage of mice developing cachexia over time. M, Percentage of cachexia-free mice at endpoint. N, Representative heart sections stained with WGA Alexa Fluor 488 and DAPI (200× magnification; scale bar, 100 μm). Representative structural features are highlighted by arrows (white, PBS/control; red, cachectic condition; blue, ADAMTSL4 knockdown). O, CSA quantification of cardiomyocytes (n = 3 per group, >200 cells per mouse). P, Cardiac expression of autophagy-related genes (Bnip3, Map1lc3, and Gabarapl1) by qPCR. Q, Western blot analysis of cardiac autophagy (LC3-I and LC3-II) and (R) apoptosis (BAX) markers. Data are presented as the mean ± SEM. Each dot represents an individual biological replicate. Statistical analysis: one-way ANOVA with Tukey multiple-comparisons test (B–D, F–I, K, and O), multiple two-tailed unpaired t tests with Welch correction (J), two-way ANOVA or mixed-effects model (REML) with Tukey multiple-comparisons test (P–R), and GSEA enrichment scores calculated using weighted Kolmogorov–Smirnov statistics (E). Significance is denoted as *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. [A, Created in BioRender. Machado, J. (2026) https://BioRender.com/79ygt3l.]

  • Open Access

    Figure 2 from Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia

    by Juliano Machado, Vignesh Karthikaisamy, Hermine Mohr, Doris Kaltenecker, Pia Benedikt, Pauline Morigny, Amit Mhamane, Julia Geppert, Amy Rose Fumo, Kerstin Haase, et al.

    Tumor-specific overexpression of ADAMTSL4 is sufficient to drive cancer cachexia. A–U, Mice were subcutaneously inoculated with control MC38-GFP cells (n = 7) or MC38 cells stably overexpressing ADAMTSL4 (MC38-ADAMTSL4; n = 9–12). A, Schematic of the preclinical model used to assess the cachexia-inducing capacity of MC38 tumor-derived ADAMTSL4. B,Adamtsl4 mRNA levels in tumors. C, Plasma ADAMTSL4 protein levels determined by Western blot analysis. D, Tumor mass. E, Food intake in tumor-bearing mice. Food intake was measured daily by weighing chow pellets at a fixed time point. Mice were housed two per cage, and total cage consumption was calculated as the difference between food provided and food remaining on the following day, with visual inspection to account for potential spillage. Intake was normalized to the number of mice per cage and expressed as grams per mouse per day. No significant differences were observed between groups across the study period. F, Initial and final carcass weight (tumor-free body weight). G, Longitudinal kinetics of relative body weight (BW) change (%) in the days preceding sacrifice. H, Spearman correlation between plasma ADAMTSL4 levels and final relative BW change (n = 18 XY pairs). Relative BW change was calculated from the longitudinal measurements shown in G. I, Relative change in fat mass measured by EchoMRI. J, Fat mass in distinct adipose depots: iWAT, eWAT, and BAT. K, Expression of lipid metabolism-related genes in iWAT assessed by qPCR. L, Relative change in lean mass measured by EchoMRI. M, TA and GC muscle weights. N, Representative images of TA muscle cross-sections stained with WGA Alexa Fluor 488 and DAPI (200× magnification; scale bar, 100 μm). Representative structural features are highlighted by arrows (white, control; red, ADAMTSL4-overexpressing condition). O, Quantification of muscle fiber CSA. P, Frequency distribution of fiber CSA in TA muscle. Q, Absolute grip strength (forelimbs and hindlimbs). N–P, Complementary readouts derived from the same TA muscle cross-section analysis. R, Grip strength normalized to lean mass (g/g). S, Selected GO terms identified by GSEA in GC muscle from MC38-ADAMTSL4 vs. MC38-GFP tumor-bearing mice (see also Supplementary Data S1 and S2 for full GO term analysis results). T, Validation of marker genes associated with proteasomal catabolic processes (Fbxo32 and Trim63). U, Validation of macroautophagy-related genes (Becn1, Map1lc3, and Gabarapl1) by qPCR. Data are presented as the mean ± SEM. Each dot represents an individual biological replicate. Statistical analysis: two-tailed unpaired t test (B–D, F, I–M, O, Q, R, T, and U), Spearman rank correlation (H), two-way mixed-effects analysis with Šídák multiple-comparisons test (E and G), and weighted Kolmogorov–Smirnov test for GSEA enrichment scores (S). Significance is denoted as *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. [A, Created in BioRender. Machado, J. (2026) https://BioRender.com/q1z1l3n.]

  • Open Access

    Figure 3 from Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia

    by Juliano Machado, Vignesh Karthikaisamy, Hermine Mohr, Doris Kaltenecker, Pia Benedikt, Pauline Morigny, Amit Mhamane, Julia Geppert, Amy Rose Fumo, Kerstin Haase, et al.

    Suppression of C26 tumor-derived ADAMTSL4 attenuates cancer cachexia and muscle atrophy in vivo. A–R, Mice were subcutaneously inoculated with PBS (n = 5), control C26 cells (C26-shCtrl, n = 10), or C26 cells with stable ADAMTSL4 knockdown (C26-shAdamtsl4, n = 9). A, Schematic overview of the preclinical model used to investigate the role of C26 tumor-derived ADAMTSL4 in cachexia. B, Adamtsl4 mRNA expression in tumors assessed by qPCR. C, Plasma ADAMTSL4 protein levels measured by Western blot. D, Tumor mass and (E) food intake in tumor-bearing or PBS-injected mice. Food intake measured daily per cage and normalized to grams per mouse per day. Mice were housed two per cage unless otherwise indicated. F, Initial body weight (iBW), final BW (fBW), and tumor-free carcass weight. G, Relative BW loss kinetics during the final days prior to sacrifice. H, Relative change in lean mass determined by EchoMRI. I, GC and TA muscle weights. J, Representative images of TA muscle sections stained with WGA Alexa Fluor 488 and DAPI (200× magnification; scale bar, 100 μm). Representative structural features are highlighted by arrows (white, PBS/control; red, cachectic condition; blue, ADAMTSL4 knockdown). K, Quantification of muscle fiber CSA (n = 3 per group, >500 fibers per mouse) and (L) fiber size distribution in TA. M, Selected GO terms from GSEA of GC muscle from C26-shCtrl vs. PBS-injected mice (see also Supplementary Data S3 and S4 for full GO term analysis results). N, Selected GO terms from GSEA of GC muscle from C26-shAdamtsl4 vs. C26-shCtrl tumor-bearing mice (see also Supplementary Data S5 and S6 for full GO term analysis results). O, Quantification of Western blot analysis of key proteins involved in proteasomal catabolism and autophagy, including p-FOXO3a at T32 and p-STAT3 at Y705. P, mRNA expression of proteasomal catabolic genes (Fbxo32 and Trim63) and (Q) autophagy-related genes (Becn1, Map1lc3, and Gabarapl1) validated by qPCR. R, Quantification of Western blot analysis of autophagy marker LC3, showing LC3-I, LC3-II, and the LC3-II/LC3-I ratio. Data are presented as the mean ± SEM. Each dot represents an individual biological replicate. Statistical analysis: two-tailed unpaired t test with Welch correction (B and D), one-way ANOVA with Tukey multiple-comparisons test (C, F, G–I, K, and O–R), two-way ANOVA with mixed-effects model (REML) followed by Tukey’s test (E and G), and GSEA enrichment scores calculated using weighted Kolmogorov–Smirnov statistics (M and N). Significance is denoted as *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. [A, Created in BioRender. Machado, J. (2026) https://BioRender.com/vx8zzgy.]

  • Open Access

    Supplementary Figures S1-S6 from Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia

    by Juliano Machado, Vignesh Karthikaisamy, Hermine Mohr, Doris Kaltenecker, Pia Benedikt, Pauline Morigny, Amit Mhamane, Julia Geppert, Amy Rose Fumo, Kerstin Haase, et al.

    Supplementary Fig. S1. ADAMTSL4 is enriched in conditioned media of cachexia-inducing cancer cell lines and is associated with systemic metabolic alterations in patients with cancer. Supplementary Fig. S2. Overexpression of ADAMTSL4 converts non-cachexia-inducing cells into cachexia-inducing cells. Supplementary Fig. S3. Stable knockdown of ADAMTSL4 in cachexia-inducing cells attenuates their muscle-wasting capacity in vitro. Supplementary Fig. S4. Stable knockdown of ADAMTSL4 in cachexia-inducing tumor cells attenuates in vitro and in vivo adipocyte wasting and prolongs cachexia-related survival. Supplementary Fig. S5. ADAMTSL4 targets LAP of latent TGF-β1 complex to promote myotube atrophy via TGF-β latency activation and TGFβR-dependent signaling. Supplementary Fig. S6. ADAMTSL4 induces wasting of murine and human white adipocytes via local activation of TGF-β1–TGFBR1 signaling, without altering circulating TGF-β1 levels.

  • Open Access

    Figure 6 from Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia

    by Juliano Machado, Vignesh Karthikaisamy, Hermine Mohr, Doris Kaltenecker, Pia Benedikt, Pauline Morigny, Amit Mhamane, Julia Geppert, Amy Rose Fumo, Kerstin Haase, et al.

    ADAMTSL4 induces skeletal muscle fibrosis via local TGFβ signaling and activates fibrosis-related genes in human myotubes and muscles of patients with cancer cachexia. A and B, GSEA (A) of GC muscle from MC38-GFP vs. MC38-ADAMTSL4 tumor-bearing mice showing enrichment of the “TGFβ receptor signaling” pathway and heatmap (B) of the top 10 DEGs within this pathway. C and D, GSEA (C) of GC muscle from C26-shCtrl vs. C26-shAdamtsl4 tumor-bearing mice showing enrichment of “TGFβ receptor signaling activates SMADs” and heatmap (D) of the top 10 DEGs. E, Representative Sirius Red (top) and collagen-I (bottom) staining in GC muscle sections from PBS-injected, C26-shCtrl, and C26-shAdamtsl4 tumor-bearing mice (scale bar, 100 μm). F–K, Human primary myotubes were treated with rhADAMTSL4-CT (250 ng/mL) in the presence or absence of TGFβ pathway blockade: (F) mRNA levels of fibrosis-related genes (TGFB1, CTGF, and TGFBI); (G) atrophy-related genes (FBXO32 and TRIM63) measured by qPCR; (H) quantification of myotube diameter; (I) representative images of myotubes treated with vehicle or rhADAMTSL4-CT ± TGFβ1–neutralizing antibody 1D11 (1.5 μg/mL; scale bar, 100 μm); (J) Western blot analysis of phosphorylated SMAD2 (p-SMAD2); (K) qPCR analysis of CTGF and TGM2 mRNA levels in myotubes treated with vehicle or rhADAMTSL4-CT ± galunisertib (10 μmol/L), a TGFBR1 inhibitor. L and M, Relative body weight change and circulating ADAMTSL4 levels measured by ELISA in an exploratory human cancer subcohort including patients with colorectal cancer and PDAC classified as cachectic (cancer cachexia, n = 15) or noncachectic (non–cancer cachexia, n = 7). N–P, qPCR analysis of TGFB1, TGM2, and FBXO21 mRNA expression in rectus abdominis muscle biopsies from non–cancer cachexia patients and those with cancer cachexia with colorectal cancer/PDAC. Q, Schematic model depicting how tumor-derived ADAMTSL4 promotes muscle wasting via local activation of TGFβ signaling through LAP engagement and TGFBR1-dependent transcriptional responses. Data are shown as the mean ± SEM unless indicated otherwise. Each dot represents one biological replicate. Statistical analysis: weighted Kolmogorov–Smirnov test for GSEA enrichment scores (A and C); two-way mixed-effects model with Tukey or Holm–Šídák multiple-comparisons test (F–H, J, and K); for circulating ADAMTSL4 measurements in human plasma (M), ELISA values were log10-transformed and analyzed using a two-tailed Mann–Whitney test; human gene expression comparisons (N–P) were analyzed using two-tailed Mann–Whitney tests. Significance is denoted as *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. [Q, Created in BioRender. Machado, J. (2026) https://BioRender.com/4sidioq.]

  • Open Access

    Supplementary Data S1-S9 from Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia

    by Juliano Machado, Vignesh Karthikaisamy, Hermine Mohr, Doris Kaltenecker, Pia Benedikt, Pauline Morigny, Amit Mhamane, Julia Geppert, Amy Rose Fumo, Kerstin Haase, et al.

    Excel spreadsheets with complete GO-enrichment analyses and TRICEPS-MS data

  • Open Access

    Figure 5 from Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia

    by Juliano Machado, Vignesh Karthikaisamy, Hermine Mohr, Doris Kaltenecker, Pia Benedikt, Pauline Morigny, Amit Mhamane, Julia Geppert, Amy Rose Fumo, Kerstin Haase, et al.

    ADAMTSL4 targets LAP of proTGFβ1 to promote myotube atrophy via latency activation and TGFBR1-dependent signaling. A and B, LRC-TriCEPS experiments were performed using C2C12 myotubes to identify surface interactors of recombinant human ADAMTSL4-CT (rhADAMTSL4-CT). Volcano plots of LC-MS/MS data comparing rhADAMTSL4-CT against glycine (negative control; A) or TRFE (positive control; B) show enrichment of membrane-associated proteins, including proTGFβ1 (UniProt P04202), as significant targets of rhADAMTSL4-CT (see also Supplementary Table S3 and Supplementary Data S9). C, Co-IP assays were performed in HEK293T cells transiently transfected with tagged constructs, followed by IP from whole-cell lysates (WCL). Using HA-tagged LAP (HA-LAP), ADAMTSL4-CT (His- or V5-tagged) was specifically detected in the precipitated complex, demonstrating a direct interaction between ADAMTSL4 and the LAP of proTGFβ1. D, Co-IP using FLAG-tagged mature TGFβ1 (FLAG–TGFβ1) did not show interaction with ADAMTSL4-CT, despite robust detection in input controls, indicating that ADAMTSL4 selectively binds LAP but not mature TGFβ1. E, Schematic representation of constructs used in NanoBiT luciferase complementation assays. ADAMTSL4 was fused to the small fragment (SmBiT), whereas LAP was fused to the large fragment (LgBiT). Upon protein–protein interaction, proximity of SmBiT and LgBiT enables luciferase reconstitution in the presence of substrate, resulting in luminescence proportional to binding. F, NanoBiT assay demonstrating interaction between ADAMTSL4-CT (ATL4-CT) and LAP in live cells. G, Schematic representation of the NanoBiT-based dissociation assay. A full-length proTGFβ1 construct was engineered to fuse LgBiT to LAP and SmBiT to the TGFβ1 domain. This design preserves physiologic endoplasmic reticulum (ER)–Golgi processing and proteolytic cleavage while maintaining the noncovalent association of LAP and mature TGFβ1 within the SLC. Disruption of the LAP–TGFβ1 interaction results in separation of LgBiT and SmBiT, leading to decreased luminescence and enabling quantitative assessment of protein–protein dissociation. H and I, ADAMTSL4 promotes dissociation of mature TGFβ1 from LAP, as measured by reduced NanoBiT luminescence signal. J, Total free TGFβ1 protein levels measured by ELISA in supernatants of C2C12 myotubes treated with vehicle or rhADAMTSL4-CT (250 ng/mL). K and L,Tgfb1 and Fbxo32 mRNA expression in C2C12 myotubes treated with vehicle or rhADAMTSL4-CT, with or without lentiviral knockdown of proTgfb1. M, Representative immunofluorescence images of C2C12 myotubes treated with vehicle or rhADAMTSL4-CT, with or without lentiviral knockdown of proTgfb1. N, Western blot analysis of phosphorylated SMAD2 (p-SMAD2) as a readout of TGFβ pathway activation in C2C12 myotubes treated with rhADAMTSL4-CT in the presence or absence of the TGFβ1–neutralizing antibody 1D11 (1.5 μg/mL). O–R, qPCR analysis of Tgfb1, Ctgf, Fbxo32, and Map1lc3 in myotubes treated with rhADAMTSL4-CT ± TGFβ1–neutralizing antibody 1D11 (1.5 μg/mL). S–X, Functional inhibition of TGFBR1 using galunisertib (10 μmol/L), LY-364947 (10 μmol/L), or SB-431542 (10 μmol/L) in the context of rhADAMTSL4-CT treatment: (S) Western blot analysis of p-SMAD2; (T and U) Ctgf and Fbxo32 mRNA expression; (V) quantification of myotube diameter; (W) representative immunofluorescence images. X, Schematic summary of the mechanistic framework uncovered in this study. ADAMTSL4 binds the LAP of proTGFβ1, as demonstrated by co-IP and NanoBiT interaction assays. This interaction promotes dissociation of the latent TGFβ1 complex, leading to the release of bioactive TGFβ1. Functionally, ADAMTSL4-induced TGFβ1 activation is inhibited by rhLAP, demonstrating the requirement of LAP engagement. Downstream signaling is blocked by the TGFβ1–neutralizing antibody 1D11, confirming ligand-dependent activation. Pharmacologic inhibition of TGFBR1 (galunisertib, LY-364947, SB-431542) and genetic suppression of proTgfb1 further establish that ADAMTSL4-driven effects on SMAD2 activation and myotube atrophy are mediated through canonical TGFβ signaling. Together, these data support a model in which ADAMTSL4 activates latent TGFβ1 via LAP binding, triggering TGFBR1-dependent signaling and atrophy-related gene programs. Data are presented as the mean ± SEM. Each dot represents an individual biological replicate. Statistical analysis: one-way ANOVA with Tukey multiple-comparisons test (F, H, and I), two-way mixed-effects model with Tukey multiple-comparisons test (J–L and N–R), and two-way mixed-effects model with Holm–Šídák multiple-comparisons test (S–V). Significance is denoted as *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. [E, Created in BioRender. Machado, J. (2026) https://BioRender.com/xis2eju; G, Created in BioRender. Machado, J. (2026) https://BioRender.com/wqwc3bb; X, Created in BioRender. Machado, J. (2026) https://BioRender.com/l2gs5ov.]

  • Open Access

    Supplementary Tables S1-S4 from Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia

    by Juliano Machado, Vignesh Karthikaisamy, Hermine Mohr, Doris Kaltenecker, Pia Benedikt, Pauline Morigny, Amit Mhamane, Julia Geppert, Amy Rose Fumo, Kerstin Haase, et al.

    Table S1: Characterization of colorectal cancer patients. Table S2: Characterization of Lung cancer adenocarcinoma stratified from NSCLC cohort, cancer cachexia cohort 3 (29). Table S3: Enrichment of proteins obtained in Ligand-receptor capture followed LC-MS/MS analysis. Table S4: RRID Addendum.

  • Open Access

    Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia

    by Juliano Machado, Vignesh Karthikaisamy, Hermine Mohr, Doris Kaltenecker, Pia Benedikt, Pauline Morigny, Amit Mhamane, Julia Geppert, Amy Rose Fumo, Kerstin Haase, et al.

    Cancer cachexia is a devastating wasting syndrome with no approved therapies. In this study, we identify the tumor-derived glycoprotein ADAMTSL4 as a circulating factor associated with body weight loss in preclinical cachexia models and patients with colorectal and lung cancers. In mice, Adamtsl4 overexpression converted non–cachexia-inducing tumors into cachexia-inducing tumors, whereas its deletion in cachexia-inducing tumors spared fat and muscle, blunted muscle atrophy signatures, and reduced cachexia severity. ADAMTSL4 engages the latency-associated peptide (LAP) of TGFβ1, promoting local activation of TGFβ1 at muscle cell membranes. Genetic blockade of proTGFβ1 or pharmacologic inhibition of TGFβ signaling reduced ADAMTSL4-dependent wasting in adipocytes and muscle cells. Suppression of tumor-derived ADAMTSL4 attenuated skeletal muscle fibrosis in mice. Together, the association between increased circulating ADAMTSL4 levels and TGFβ–driven muscle atrophy and fibrosis gene signatures in patients with cachectic cancer identifies ADAMTSL4 as an upstream regulator of TGFβ1 and a potential therapeutic target in cancer cachexia. Significance: Cancer cachexia lacks effective therapies and remains a major cause of cancer-related morbidity and mortality. We identify tumor-derived ADAMTSL4 as an upstream regulator of latent TGFβ activation via LAP engagement that promotes multiorgan wasting and fibrosis-related remodeling. Targeting ADAMTSL4 may provide a selective therapeutic strategy without systemic TGFβ pathway blockade. See related commentary by Liu and Janowitz, p. 1964